Market cap of Alaunos Therapeutics Inc. [TCRT] reaches 102.29M – now what?



Alaunos Therapeutics Inc. [NASDAQ: TCRT] closed the trading session at $0.46 on 04/21/22. The day’s price range saw the stock hit a low of $0.4411, while the highest price level was $0.4799. The company report on March 30, 2022 that Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications; first patient consented and is expected to dose in 2Q 2022.

Extended CRADA with the National Cancer Institute focused on evaluating Alaunos’ TCR-T Library in a personalized TCR-T program.

The stocks have a year to date performance of -57.91 percent and weekly performance of -7.14 percent. The stock has been moved at -72.53 percent over the last six months. The stock has performed -35.55 percent around the most recent 30 days and changed -46.71 percent over the most recent 3-months.

If compared to the average trading volume of 2.20M shares, TCRT reached to a volume of 2834918 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Alaunos Therapeutics Inc. [TCRT]:

The Average True Range (ATR) for Alaunos Therapeutics Inc. is set at 0.06, with the Price to Sales ratio for TCRT stock in the period of the last 12 months amounting to 255.74. The Price to Book ratio for the last quarter was 1.70, with the Price to Cash per share for the same quarter was set at 0.34.

TCRT stock trade performance evaluation

Alaunos Therapeutics Inc. [TCRT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.14. With this latest performance, TCRT shares dropped by -35.55% in over the last four-week period, additionally sinking by -72.53% over the last 6 months – not to mention a drop of -86.30% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TCRT stock in for the last two-week period is set at 33.76, with the RSI for the last a single of trading hit 32.82, and the three-weeks RSI is set at 35.87 for Alaunos Therapeutics Inc. [TCRT]. The present Moving Average for the last 50 days of trading for this stock 0.7195, while it was recorded at 0.4426 for the last single week of trading, and 1.3709 for the last 200 days.

Alaunos Therapeutics Inc. [TCRT]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Alaunos Therapeutics Inc. [TCRT] shares currently have an operating margin of -18379.90. Alaunos Therapeutics Inc.’s Net Margin is presently recorded at -19786.68.

Return on Equity for this stock declined to -86.52, with Return on Assets sitting at -65.30.

Alaunos Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.90 and a Current Ratio set at 4.90.

Alaunos Therapeutics Inc. [TCRT]: Insider Ownership positions

There are presently around $51 million, or 59.10% of TCRT stock, in the hands of institutional investors. The top three institutional holders of TCRT stocks are: BLACKROCK INC. with ownership of 16,764,972, which is approximately -1.008% of the company’s market cap and around 0.50% of the total institutional ownership; MSD PARTNERS, L.P., holding 15,151,516 shares of the stock with an approximate value of $6.74 million in TCRT stocks shares; and DISCOVERY CAPITAL MANAGEMENT, LLC / CT, currently with $5.94 million in TCRT stock with ownership of nearly 6.376% of the company’s market capitalization.

Positions in Alaunos Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 75 institutional holders increased their position in Alaunos Therapeutics Inc. [NASDAQ:TCRT] by around 16,558,503 shares. Additionally, 72 investors decreased positions by around 8,440,099 shares, while 38 investors held positions by with 88,545,358 shares. The mentioned changes placed institutional holdings at 113,543,960 shares, according to the latest SEC report filing. TCRT stock had 25 new institutional investments in for a total of 4,523,632 shares, while 19 institutional investors sold positions of 999,306 shares during the same period.